


### REMARKS

Claim 20 has been amended to recite the administration of escitalopram as "the sole active ingredient" to treat patients suffering from attention deficit hyperactivity disorder. Support for amended claim 20 is found in the specification at, for example, page 4, lines 21-22, and page 5, line 29, to page 6, line 1. Claims 20-37 are pending.

Respectfully submitted,

Dated: August 5, 2004

By: \_\_\_\_\_



Jay Lessler  
Reg. No. 41,151  
Attorney for Applicants

Darby & Darby P.C.  
Post Office Box 5257  
New York, NY 10150-5257  
212-527-7700